Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281649129> ?p ?o ?g. }
- W4281649129 endingPage "2873" @default.
- W4281649129 startingPage "2873" @default.
- W4281649129 abstract "Despite the durable remissions induced by ICIs and targeted therapies in advanced melanoma and non-melanoma skin cancers, both subtypes usually relapse. Many systematic therapies have been tested to increase efficacy and delay relapse in ICIs, but their success has been limited. Due the feasibility of this approach, skin cancers have become the ideal platform for intralesional infusions of many novel agents, including oncolytic viruses (OVs). Talimogene laherparepvec (T-VEC) was the first FDA-approved OV for the treatment of unresectable melanoma and this virus opened up further potential for the use of this class of agents, especially in combination with ICIs, in order to achieve deeper and longer immune-mediated responses. However, the recently announced phase III MASTERKEY-265 trial was not able to confirm that the addition of T-VEC to pembrolizumab treatment improves progression-free or overall survival over the use of pembrolizumab alone. Despite these results, numerous studies are currently active, evaluating T-VEC and several other OVs as monotherapies or in regimens with ICIs in different subtypes of skin cancer. This overview provides a comprehensive update on the evolution status of all available OVs in melanoma and non-melanoma skin cancers and summarizes the more interesting preclinical findings, the latest clinical evidence, and the future insights in relation to the expected selective incorporation of some of these OVs into oncological practice." @default.
- W4281649129 created "2022-06-13" @default.
- W4281649129 creator A5026175666 @default.
- W4281649129 creator A5045049808 @default.
- W4281649129 creator A5058973451 @default.
- W4281649129 creator A5080248261 @default.
- W4281649129 creator A5090633646 @default.
- W4281649129 date "2022-06-10" @default.
- W4281649129 modified "2023-10-14" @default.
- W4281649129 title "Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers" @default.
- W4281649129 cites W1970368422 @default.
- W4281649129 cites W1977890900 @default.
- W4281649129 cites W1980973208 @default.
- W4281649129 cites W2008905972 @default.
- W4281649129 cites W2030479138 @default.
- W4281649129 cites W2039263693 @default.
- W4281649129 cites W2042793636 @default.
- W4281649129 cites W2046300989 @default.
- W4281649129 cites W2056650797 @default.
- W4281649129 cites W2058531798 @default.
- W4281649129 cites W2063512646 @default.
- W4281649129 cites W2082150850 @default.
- W4281649129 cites W2086591619 @default.
- W4281649129 cites W2091913868 @default.
- W4281649129 cites W2099648846 @default.
- W4281649129 cites W2109274792 @default.
- W4281649129 cites W2115846714 @default.
- W4281649129 cites W2117218953 @default.
- W4281649129 cites W2126373038 @default.
- W4281649129 cites W2134391698 @default.
- W4281649129 cites W2135039865 @default.
- W4281649129 cites W2136443494 @default.
- W4281649129 cites W2165320653 @default.
- W4281649129 cites W2177826333 @default.
- W4281649129 cites W2179173820 @default.
- W4281649129 cites W2207677213 @default.
- W4281649129 cites W2215070146 @default.
- W4281649129 cites W2475725119 @default.
- W4281649129 cites W2494461917 @default.
- W4281649129 cites W2494612254 @default.
- W4281649129 cites W2585359117 @default.
- W4281649129 cites W2602107020 @default.
- W4281649129 cites W2606495925 @default.
- W4281649129 cites W2693520548 @default.
- W4281649129 cites W2734544901 @default.
- W4281649129 cites W2736194991 @default.
- W4281649129 cites W2756324556 @default.
- W4281649129 cites W2763265527 @default.
- W4281649129 cites W2773106490 @default.
- W4281649129 cites W2805968856 @default.
- W4281649129 cites W2808686638 @default.
- W4281649129 cites W2889085114 @default.
- W4281649129 cites W2890653531 @default.
- W4281649129 cites W2890744606 @default.
- W4281649129 cites W2890886223 @default.
- W4281649129 cites W2898003394 @default.
- W4281649129 cites W2898688304 @default.
- W4281649129 cites W2901878567 @default.
- W4281649129 cites W2948662515 @default.
- W4281649129 cites W2949375297 @default.
- W4281649129 cites W2967139876 @default.
- W4281649129 cites W2967162008 @default.
- W4281649129 cites W2977847764 @default.
- W4281649129 cites W2983347147 @default.
- W4281649129 cites W2991485222 @default.
- W4281649129 cites W3001836957 @default.
- W4281649129 cites W3013373122 @default.
- W4281649129 cites W3043818052 @default.
- W4281649129 cites W3045668696 @default.
- W4281649129 cites W3047382685 @default.
- W4281649129 cites W3098713621 @default.
- W4281649129 cites W3099726794 @default.
- W4281649129 cites W3104348248 @default.
- W4281649129 cites W3104746911 @default.
- W4281649129 cites W3122662118 @default.
- W4281649129 cites W3127944285 @default.
- W4281649129 cites W3144959724 @default.
- W4281649129 cites W3157660299 @default.
- W4281649129 cites W3166578944 @default.
- W4281649129 cites W3167691461 @default.
- W4281649129 cites W3168238345 @default.
- W4281649129 cites W3169367174 @default.
- W4281649129 cites W3182433262 @default.
- W4281649129 cites W3184066167 @default.
- W4281649129 cites W3199488360 @default.
- W4281649129 cites W3201686202 @default.
- W4281649129 cites W3203317065 @default.
- W4281649129 cites W3203855951 @default.
- W4281649129 cites W3210054708 @default.
- W4281649129 cites W4200525828 @default.
- W4281649129 cites W4205882487 @default.
- W4281649129 cites W4224315108 @default.
- W4281649129 cites W4225394054 @default.
- W4281649129 doi "https://doi.org/10.3390/cancers14122873" @default.
- W4281649129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35740539" @default.
- W4281649129 hasPublicationYear "2022" @default.
- W4281649129 type Work @default.
- W4281649129 citedByCount "0" @default.